Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Current Deferred Revenue (2017 - 2026)

Bioceres Crop Solutions' Current Deferred Revenue history spans 8 years, with the latest figure at $2.8 million for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 million, a N/A change, with the full-year FY2025 number at $4.3 million, changed N/A from a year prior.
  • Current Deferred Revenue hit $2.8 million in Q1 2026 for Bioceres Crop Solutions, down from $4.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BIOX hit a ceiling of $4.3 million in Q2 2025 and a floor of $295000.0 in Q2 2022.
  • Historically, Current Deferred Revenue has averaged $2.5 million across 3 years, with a median of $2.8 million in 2026.
  • The widest YoY moves for Current Deferred Revenue: up 95.3% in 2022, down 95.3% in 2022.
  • Tracing BIOX's Current Deferred Revenue over 3 years: stood at $295000.0 in 2022, then soared by 1357.63% to $4.3 million in 2025, then crashed by 34.88% to $2.8 million in 2026.
  • Business Quant data shows Current Deferred Revenue for BIOX at $2.8 million in Q1 2026, $4.3 million in Q2 2025, and $295000.0 in Q2 2022.